Hepsana - Étude de Cas Médicament 2023

Specialists in liver diseases

About Hepsana - Étude de Cas Médicament 2023

Specializing in liver diseases, this laboratory founded by researchers and venture capitalists focuses on innovative therapies through student-created pharmaceutical brands

Key facts

Industry: Pharmaceutical Manufacturing
Company size: 1–10 employees
Headquarters: Orsay, Île-de-France, France
Revenue: $2.9M – $22.7MTamtam estimate
LinkedIn: linkedin.com/company/edcmedicament

Hepsana - Étude de Cas Médicament 2023 at a glance

Hepsana - Étude de Cas Médicament 2023 is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Orsay, Île-de-France, France.

Hepsana - Étude de Cas Médicament 2023 has 1–10 employees.

Hepsana - Étude de Cas Médicament 2023's revenue is $2.9M – $22.7M (Tamtam estimate).

Frequently asked questions about Hepsana - Étude de Cas Médicament 2023

What is Hepsana - Étude de Cas Médicament 2023's revenue?

Tamtam estimates Hepsana - Étude de Cas Médicament 2023's annual revenue at $2.9M – $22.7M.

How many employees does Hepsana - Étude de Cas Médicament 2023 have?

Hepsana - Étude de Cas Médicament 2023 has 1–10 employees.

Where is Hepsana - Étude de Cas Médicament 2023 headquartered?

Hepsana - Étude de Cas Médicament 2023 is headquartered in Orsay, Île-de-France, France.

Selling to companies like Hepsana - Étude de Cas Médicament 2023?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies